Phagenesis raises $42m to take medical device for swallowing disorders to the US
The startup received FDA clearance for its medical device in the US in 2022 and is now looking to commercialise its product in the country
K medtech startup Phagenesis has raised a $42m Series D to roll out its medical device for swallowing disorders in the US and expand its footprint in Europe. The round was co-led by Netherlands-based EQT Life Sciences and Canada-based Sectoral Asset Management. British Patient Capital, Northern Gritstone and Aphelion also participated. The cash will also be used to fund clinical trials, regulatory approval processes and developing the company’s pipeline of products.
